{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T18:13:08Z","timestamp":1773166388260,"version":"3.50.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21J13988"],"award-info":[{"award-number":["21J13988"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["20H04699"],"award-info":[{"award-number":["20H04699"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    A total of 42 trisubstituted carboranes categorised into five scaffolds were systematically designed and synthesized by exploiting the different reactivities of the twelve vertices of\n                    <jats:italic>o-<\/jats:italic>\n                    ,\n                    <jats:italic>m<\/jats:italic>\n                    -, and\n                    <jats:italic>p<\/jats:italic>\n                    -carboranes to cover all directions in chemical space. Significant inhibitors of hypoxia inducible factor transcriptional activitay were mainly observed among scaffold V compounds (e.g.,\n                    <jats:bold>Vi\u2013m<\/jats:bold>\n                    , and\n                    <jats:bold>Vo<\/jats:bold>\n                    ), whereas anti-rabies virus activity was observed among scaffold V (\n                    <jats:bold>Va\u2013h<\/jats:bold>\n                    ), scaffold II (\n                    <jats:bold>IIb\u2013g<\/jats:bold>\n                    ), and scaffold IV (\n                    <jats:bold>IVb<\/jats:bold>\n                    ) compounds. The pharmacophore model predicted from compounds with scaffold V, which exhibited significant anti-rabies virus activity, agreed well with compounds\n                    <jats:bold>IIb\u2013g<\/jats:bold>\n                    with scaffold II and compound IVb with scaffold IV. Normalized principal moment of inertia analysis indicated that carboranes with scaffolds I\u2013V cover all regions in the chemical space. Furthermore, the first compounds shown to stimulate the proliferation of the rabies virus were found among scaffold V carboranes.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-03459-6","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T06:07:13Z","timestamp":1639634833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comprehensive exploration of chemical space using trisubstituted carboranes"],"prefix":"10.1038","volume":"11","author":[{"given":"Yasunobu","family":"Asawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saki","family":"Hatsuzawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Yoshimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kentaro","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Katoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Kouji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"3459_CR1","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1038\/nature03192","volume":"432","author":"L Odling-smee","year":"2004","unstructured":"Odling-smee, L. & Dobson, C. M. Insight chemical space and biology. Nature 432, 824\u2013828 (2004).","journal-title":"Nature"},{"key":"3459_CR2","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.drudis.2012.10.008","volume":"18","author":"A Barker","year":"2013","unstructured":"Barker, A., Kettle, J. G., Nowak, T. & Pease, J. E. Expanding medicinal chemistry space. Drug Discov. Today 18, 298\u2013304 (2013).","journal-title":"Drug Discov. Today"},{"key":"3459_CR3","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1039\/b402985m","volume":"22","author":"MS Butler","year":"2005","unstructured":"Butler, M. S. Natural products to drugs: Natural product derived compounds in clinical trials. Nat. Prod. Rep. 22, 162\u2013195 (2005).","journal-title":"Nat. Prod. Rep."},{"key":"3459_CR4","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/np068054v","volume":"70","author":"DJ Newman","year":"2007","unstructured":"Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 70, 461\u2013477 (2007).","journal-title":"J. Nat. Prod."},{"key":"3459_CR5","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1021\/acs.jnatprod.5b01055","volume":"79","author":"DJ Newman","year":"2016","unstructured":"Newman, D. J. & Cragg, G. M. Natural products as sources of new drugs from 1981 to 2014. J. Nat. Prod. 79, 629\u2013661 (2016).","journal-title":"J. Nat. Prod."},{"key":"3459_CR6","doi-asserted-by":"publisher","first-page":"6752","DOI":"10.1021\/jm901241e","volume":"52","author":"F Lovering","year":"2009","unstructured":"Lovering, F., Bikker, J. & Humblet, C. Escape from flatland: Increasing saturation as an approach to improving clinical success. J. Med. Chem. 52, 6752\u20136756 (2009).","journal-title":"J. Med. Chem."},{"key":"3459_CR7","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1039\/c2md20347b","volume":"4","author":"F Lovering","year":"2013","unstructured":"Lovering, F. Escape from Flatland 2: Complexity and promiscuity. Medchemcomm 4, 515\u2013519 (2013).","journal-title":"Medchemcomm"},{"key":"3459_CR8","doi-asserted-by":"publisher","first-page":"6609","DOI":"10.1021\/acs.jmedchem.8b00194","volume":"61","author":"FM Tajabadi","year":"2018","unstructured":"Tajabadi, F. M. et al. Design and synthesis of natural product inspired libraries based on the three-dimensional (3D) cedrane scaffold: Toward the exploration of 3D biological space. J. Med. Chem. 61, 6609\u20136628 (2018).","journal-title":"J. Med. Chem."},{"key":"3459_CR9","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1126\/science.287.5460.1964","volume":"287","author":"SL Schreiber","year":"2000","unstructured":"Schreiber, S. L. Target-oriented and diversity-oriented organic synthesis in drug discovery. Science 287, 1964\u20131969 (2000).","journal-title":"Science"},{"key":"3459_CR10","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/457153a","volume":"457","author":"SL Schreiber","year":"2009","unstructured":"Schreiber, S. L. Molecular diversity by design. Nature 457, 153\u2013154 (2009).","journal-title":"Nature"},{"key":"3459_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms1081","volume":"1","author":"WRJD Galloway","year":"2010","unstructured":"Galloway, W. R. J. D., Isidro-Llobet, A. & Spring, D. R. Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. Nat. Commun. 1, 1\u201313 (2010).","journal-title":"Nat. Commun."},{"key":"3459_CR12","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/nchembio.911","volume":"8","author":"F Kopp","year":"2012","unstructured":"Kopp, F., Stratton, C. F., Akella, L. B. & Tan, D. S. A diversity-oriented synthesis approach to macrocycles via oxidative ring expansion. Nat. Chem. Biol. 8, 358\u2013365 (2012).","journal-title":"Nat. Chem. Biol."},{"key":"3459_CR13","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1038\/nchem.1729","volume":"5","author":"HSG Beckmann","year":"2013","unstructured":"Beckmann, H. S. G. et al. A strategy for the diversity-oriented synthesis of macrocyclic scaffolds using multidimensional coupling. Nat. Chem. 5, 861\u2013867 (2013).","journal-title":"Nat. Chem."},{"key":"3459_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms13196","volume":"7","author":"J Kim","year":"2016","unstructured":"Kim, J. et al. Diversity-oriented synthetic strategy for developing a chemical modulator of protein-protein interaction. Nat. Commun. 7, 1\u201310 (2016).","journal-title":"Nat. Commun."},{"key":"3459_CR15","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1021\/cr00010a002","volume":"92","author":"VI Bregadze","year":"1992","unstructured":"Bregadze, V. I. Dicarba-closo-dodecaboranes C2B10H12 and their derivatives. Chem. Rev 92, 209\u2013223 (1992).","journal-title":"Chem. Rev"},{"key":"3459_CR16","doi-asserted-by":"publisher","first-page":"5701","DOI":"10.1021\/cr2000866","volume":"111","author":"F Issa","year":"2011","unstructured":"Issa, F., Kassiou, M., Rendina, L. M. & Rendina, M. Boron in drug discovery: Carboranes as uniquie pharmacophores in biologically active compounds. Chem. Rev. 111, 5701\u20135722 (2011).","journal-title":"Chem. Rev."},{"key":"3459_CR17","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1248\/cpb.47.585","volume":"47","author":"Y Endo","year":"1999","unstructured":"Endo, Y. et al. Dicarba-closo-dodecaboranes as a pharmacophore. Novel potent retinoidal agonists. Chem. Pharm. Bull. 47, 585\u2013587 (1999).","journal-title":"Chem. Pharm. Bull."},{"key":"3459_CR18","doi-asserted-by":"publisher","first-page":"7035","DOI":"10.1021\/cr200038x","volume":"111","author":"M Scholz","year":"2011","unstructured":"Scholz, M. & Hey-Hawkins, E. Carbaboranes as pharmacophores: Properties, synthesis, and application strategies. Chem. Rev. 111, 7035\u20137062 (2011).","journal-title":"Chem. Rev."},{"key":"3459_CR19","doi-asserted-by":"publisher","first-page":"7738","DOI":"10.1021\/acs.jmedchem.5b01932","volume":"59","author":"ZJ Le\u015bnikowski","year":"2016","unstructured":"Le\u015bnikowski, Z. J. Challenges and opportunities for the application of boron clusters in drug design. J. Med. Chem. 59, 7738\u20137758 (2016).","journal-title":"J. Med. Chem."},{"key":"3459_CR20","doi-asserted-by":"publisher","first-page":"3497","DOI":"10.1039\/C9CS00197B","volume":"48","author":"P Stockmann","year":"2019","unstructured":"Stockmann, P., Gozzi, M., Kuhnert, R., S\u00e1rosi, M. B. & Hey-Hawkins, E. New keys for old locks: Carborane-containing drugs as platforms for mechanism-based therapies. Chem. Soc. Rev. 48, 3497\u20133512 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"3459_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S1074-5521(01)00016-3","volume":"8","author":"Y Endo","year":"2001","unstructured":"Endo, Y. et al. Potent estrogen agonists based on carborane as a hydrophobic skeletal structure: A new medicinal application of boron clusters. Chem. Biol. 8, 341\u2013355 (2001).","journal-title":"Chem. Biol."},{"key":"3459_CR22","doi-asserted-by":"publisher","first-page":"3283","DOI":"10.1021\/jm0701977","volume":"50","author":"RC Reynolds","year":"2007","unstructured":"Reynolds, R. C. et al. Novel boron-containing, nonclassical antifolates: Synthesis and preliminary biological and structural evaluation. J. Med. Chem. 50, 3283\u20133289 (2007).","journal-title":"J. Med. Chem."},{"key":"3459_CR23","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/j.bmcl.2009.12.037","volume":"20","author":"K Shimizu","year":"2010","unstructured":"Shimizu, K. et al. Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1\u03b1 inhibitors. Bioorg. Med. Chem. Lett. 20, 1453\u20131456 (2010).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"3459_CR24","doi-asserted-by":"publisher","first-page":"11870","DOI":"10.1021\/ja104739t","volume":"132","author":"HS Ban","year":"2010","unstructured":"Ban, H. S., Shimizu, K., Minegishi, H. & Nakamura, H. Identification of HSP60 as a primary target of o-carboranylphenoxyacetanilide, an HIF-1\u03b1 Inhibitor. J. Am. Chem. Soc. 132, 11870\u201311871 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"3459_CR25","doi-asserted-by":"publisher","first-page":"4808","DOI":"10.1073\/pnas.0700316104","volume":"104","author":"RL Julius","year":"2007","unstructured":"Julius, R. L. et al. Synthesis and evaluation of transthyretin amyloidosis inhibitors containing carborane pharmacophores. Proc. Natl. Acad. Sci. USA 104, 4808\u20134813 (2007).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3459_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/cmdc.201500199","volume":"11","author":"W Neumann","year":"2016","unstructured":"Neumann, W. et al. Nido-dicarbaborate induces potent and selective inhibition of cyclooxygenase-2. ChemMedChem 11, 175\u2013178 (2016).","journal-title":"ChemMedChem"},{"key":"3459_CR27","doi-asserted-by":"publisher","first-page":"20933","DOI":"10.1021\/ja208797n","volume":"133","author":"S Fujii","year":"2011","unstructured":"Fujii, S. et al. Boron cluster-based development of potent nonsecosteroidal vitamin D receptor ligands: Direct observation of hydrophobic interaction between protein surface and carborane. J. Am. Chem. Soc. 133, 20933\u201320941 (2011).","journal-title":"J. Am. Chem. Soc."},{"key":"3459_CR28","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1039\/C5SC03084F","volume":"7","author":"R Otero","year":"2016","unstructured":"Otero, R. et al. Carborane-based design of a potent vitamin D receptor agonist. Chem. Sci. 7, 1033\u20131037 (2016).","journal-title":"Chem. Sci."},{"key":"3459_CR29","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1021\/jm300740t","volume":"55","author":"MW Lee","year":"2012","unstructured":"Lee, M. W., Sevryugina, Y. V., Khan, A. & Ye, S. Q. Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase. J. Med. Chem. 55, 7290\u20137294 (2012).","journal-title":"J. Med. Chem."},{"key":"3459_CR30","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1016\/j.bmc.2019.05.013","volume":"27","author":"Y Asawa","year":"2019","unstructured":"Asawa, Y. et al. Structure-based drug design of novel carborane-containing nicotinamide phosphoribosyltransferase inhibitors. Bioorg. Med. Chem. 27, 2832\u20132844 (2019).","journal-title":"Bioorg. Med. Chem."},{"key":"3459_CR31","doi-asserted-by":"publisher","first-page":"3660","DOI":"10.1039\/C9CS00169G","volume":"48","author":"Y Quan","year":"2019","unstructured":"Quan, Y. & Xie, Z. Controlled functionalization of o-carborane via transition metal catalyzed B-H activation. Chem. Soc. Rev. 48, 3660\u20133673 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"3459_CR32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1246\/bcsj.20200366","volume":"94","author":"YK Au","year":"2021","unstructured":"Au, Y. K. & Xie, Z. Recent advances in transition metal-catalyzed selective B-H functionalization of o-carboranes. Bull. Chem. Soc. Jpn. 94, 879\u2013899 (2021).","journal-title":"Bull. Chem. Soc. Jpn."},{"key":"3459_CR33","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1016\/j.bmc.2018.05.002","volume":"26","author":"H Ueda","year":"2018","unstructured":"Ueda, H., Yoshimori, A. & Nakamura, H. Discovery of bicyclo [3, 3, 1] non-2-ene as a novel skeleton for HIF-1 inhibitors. Bioorg. Med. Chem. 26, 3345\u20133351 (2018).","journal-title":"Bioorg. Med. Chem."},{"key":"3459_CR34","doi-asserted-by":"publisher","first-page":"11888","DOI":"10.1002\/chem.202101440","volume":"27","author":"K Umedera","year":"2021","unstructured":"Umedera, K. et al. Synthesis of three-dimensional (3D) (Di)azatricyclododecene scaffold and its application to peptidomimetics. Chem. A Eur. J. 27, 11888\u201311894 (2021).","journal-title":"Chem. A Eur. J."},{"key":"3459_CR35","doi-asserted-by":"publisher","first-page":"115949","DOI":"10.1016\/j.bmc.2020.115949","volume":"30","author":"T Shimizu","year":"2021","unstructured":"Shimizu, T. et al. Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1\u03b1. Bioorganic Med. Chem. 30, 115949 (2021).","journal-title":"Bioorganic Med. Chem."},{"key":"3459_CR36","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1073\/pnas.93.1.13","volume":"93","author":"S Jones","year":"1996","unstructured":"Jones, S. & Thornton, J. M. Review principles of protein\u2013protein interactions. Proc. Natl. Acad. Sci. USA 93, 13\u201320 (1996).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3459_CR37","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/nchem.1568","volume":"5","author":"V Azzarito","year":"2013","unstructured":"Azzarito, V., Long, K., Murphy, N. S. & Wilson, A. J. Inhibition of \u03b1-helix-mediated protein\u2013protein interactions using designed molecules. Nat. Chem. 5, 161\u2013173 (2013).","journal-title":"Nat. Chem."},{"key":"3459_CR38","doi-asserted-by":"publisher","first-page":"8896","DOI":"10.1002\/anie.201412070","volume":"54","author":"M Pelay-Gimeno","year":"2015","unstructured":"Pelay-Gimeno, M., Glas, A., Koch, O. & Grossmann, T. N. Structure-based design of inhibitors of protein-protein interactions: Mimicking peptide binding epitopes. Angew. Chemie Int. Ed. 54, 8896\u20138927 (2015).","journal-title":"Angew. Chemie Int. Ed."},{"key":"3459_CR39","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10989-019-09831-5","volume":"26","author":"L Mabonga","year":"2020","unstructured":"Mabonga, L. & Kappo, A. P. Peptidomimetics: A synthetic tool for inhibiting protein\u2013protein interactions in cancer. Int. J. Pept. Res. Ther. 26, 225\u2013241 (2020).","journal-title":"Int. J. Pept. Res. Ther."},{"key":"3459_CR40","first-page":"2615","volume":"59","author":"J Adams","year":"1999","unstructured":"Adams, J. et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59, 2615\u20132622 (1999).","journal-title":"Cancer Res."},{"key":"3459_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nbt1273","volume":"25","author":"AC Cheng","year":"2007","unstructured":"Cheng, A. C. et al. Structure-based maximal affinity model predicts small-molecule druggability. Nat. Biotechnol. 25, 71\u201375 (2007).","journal-title":"Nat. Biotechnol."},{"key":"3459_CR42","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"3459_CR43","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.275.5302.983","volume":"275","author":"M Sattler","year":"1997","unstructured":"Sattler, M. et al. Structure of Bcl-x(L)-Bak peptide complex: Recognition between regulators of apoptosis. Science 275, 983\u2013986 (1997).","journal-title":"Science"},{"key":"3459_CR44","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1158\/0008-5472.CAN-16-1248","volume":"76","author":"CM Croce","year":"2016","unstructured":"Croce, C. M. & Reed, J. C. Finally, an apoptosis-targeting therapeutic for cancer. Cancer Res. 76, 5914\u20135920 (2016).","journal-title":"Cancer Res."},{"key":"3459_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1021\/jm061152t","volume":"50","author":"M Bruncko","year":"2007","unstructured":"Bruncko, M. et al. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J. Med. Chem. 50, 641\u2013662 (2007).","journal-title":"J. Med. Chem."},{"key":"3459_CR46","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrd1343","volume":"3","author":"MMR Arkin","year":"2004","unstructured":"Arkin, M. M. R. & Wells, J. A. Small-molecule inhibitors of protein-protein interactions: Progressing towards the dream. Nat. Rev. Drug Discov. 3, 301\u2013317 (2004).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3459_CR47","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1021\/ol1003143","volume":"12","author":"P To\u0161ovsk\u00e1","year":"2010","unstructured":"To\u0161ovsk\u00e1, P. & Arora, P. S. Oligooxopiperazines as nonpeptidic \u03b1-helix mimetics. Org. Lett. 12, 1588\u20131591 (2010).","journal-title":"Org. Lett."},{"key":"3459_CR48","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s10930-007-9108-x","volume":"27","author":"C Yan","year":"2008","unstructured":"Yan, C., Wu, F., Jernigan, R. L., Dobbs, D. & Honavar, V. Characterization of protein\u2013protein interfaces. Protein J. 27, 59\u201370 (2008).","journal-title":"Protein J."},{"key":"3459_CR49","doi-asserted-by":"publisher","first-page":"8274","DOI":"10.1021\/acs.inorgchem.6b01667","volume":"55","author":"LM Wingen","year":"2016","unstructured":"Wingen, L. M. & Scholz, M. S. B-Cyanodicarba-closo-dodecaboranes: Facile synthesis and spectroscopic features. Inorg. Chem. 55, 8274\u20138276 (2016).","journal-title":"Inorg. Chem."},{"key":"3459_CR50","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1002\/ejic.201000064","volume":"10","author":"A Himmelspach","year":"2010","unstructured":"Himmelspach, A. & Finze, M. Dicarba-closo-dodecaboranes with one and two ethynyl groups bonded to boron. Eur. J. Inorg. Chem. 10, 2012\u20132024 (2010).","journal-title":"Eur. J. Inorg. Chem."},{"key":"3459_CR51","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/cmdc.201200502","volume":"8","author":"H Minegishi","year":"2013","unstructured":"Minegishi, H., Matsukawa, T. & Nakamura, H. Synthesis and biological evaluation of diaryl-substituted carboranes as inhibitors of hypoxia inducible factor (HIF)-1 transcriptional activity. ChemMedChem 8, 265\u2013271 (2013).","journal-title":"ChemMedChem"},{"key":"3459_CR52","doi-asserted-by":"publisher","first-page":"5510","DOI":"10.1021\/acs.inorgchem.7b00680","volume":"56","author":"MS Scholz","year":"2017","unstructured":"Scholz, M. S. & Wingen, L. M. Synthesis of Dicarba-closo-dodecaborane-1-carboxamides. Inorg. Chem. 56, 5510\u20135513 (2017).","journal-title":"Inorg. Chem."},{"key":"3459_CR53","doi-asserted-by":"publisher","first-page":"115207","DOI":"10.1016\/j.bmc.2019.115207","volume":"28","author":"S Fuse","year":"2020","unstructured":"Fuse, S. et al. Design, synthesis, and evaluation of indeno[2,1-c]pyrazolones for use as inhibitors against hypoxia-inducible factor (HIF)-1 transcriptional activity. Bioorg. Med. Chem. 28, 115207 (2020).","journal-title":"Bioorg. Med. Chem."},{"key":"3459_CR54","doi-asserted-by":"publisher","first-page":"7948","DOI":"10.1128\/JVI.00554-09","volume":"83","author":"X Lahaye","year":"2009","unstructured":"Lahaye, X. et al. Functional characterization of Negribodies (NBs) in rabies virus-infected cells: Evidence that NBs are sites of viral transcription and replication. J. Virol. 83, 7948\u20137958 (2009).","journal-title":"J. Virol."},{"key":"3459_CR55","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1021\/ci025599w","volume":"43","author":"WHB Sauer","year":"2003","unstructured":"Sauer, W. H. B. & Schwarz, M. K. Molecular shape diversity of combinatorial libraries: A prerequisite for broad bioactivity. J. Chem. Inf. Comput. Sci. 43, 987\u20131003 (2003).","journal-title":"J. Chem. Inf. Comput. Sci."},{"key":"3459_CR56","unstructured":"RDKit: Cheminformatics and machine learning software (2013). http:\/\/www.rdkit.org. Accessed 7 Dec 2021."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03459-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T13:23:06Z","timestamp":1670073786000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-03459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["3459"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-03459-6","relation":{"has-review":[{"id-type":"doi","id":"10.32388\/HO92H6","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]},"assertion":[{"value":"7 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24101"}}